Comparison of patients eligible for the PEGASUS (60 mg ticagrelor with patients eligible for PEGASUS identified from the ACTION Registry-GWTG
| Characteristics |
PEGASUS trial patients (n=7045) |
PEGASUS trial eligible in the ACTION Registry–GWTG (n=83 871) |
| Patient demographics | ||
| Age, mean (SD) | 65.2 (8.4) | 69.4 (9.5) |
| Men, n (%) | 5384 (76.4) | 51 117 (60.9) |
| White | 6077 (86.3) | 73 232 (87.3) |
| Patient medical history | ||
| Diabetes, n (%) | 2308 (32.8) | 29 704 (35.4) |
| Hypertension, n (%) | 5461 (77.5) | 64 472 (76.9) |
| Peripheral arterial disease, n (%) | 368 (5.2) | 6401 (7.6) |
| Prior MI, n (%) | 1168 (16.6) | 15 763 (18.8) |
| Chronic kidney disease, n (%) | ||
| ≥Stage 3 | 1547/6955 (22.2) | 25 551 (30.5) |
| MI characteristics and management | ||
| Presentation, n (%) | ||
| STEMI | 3757/7035 (53.4) | 33 609 (40.1) |
| NSTEMI | 2842/7035 (40.4) | 50 262 (59.9) |
| Medications | ||
| Beta-blocker | 5796 (82.3) | 77 552 (92.5) |
| ACE inhibitor or ARB | 5631 (79.9) | 57 352 (68.4) |
| Statin | 6495 (92.2) | 77 181 (92.0) |
| Aspirin at any dose | 7036 (99.9) | 81 155 (96.8) |
| Ischaemic outcomes at 3 years | ||
| MI | 285 (4.5%) | 10 889 (13.0%) |
| Stroke | 91 (1.5%) | 1447 (1.7%) |
ACTION Registry–GWTG, Acute Coronary Treatment and Intervention Outcomes Network Registry–Get With The Guidelines; ARB, angiotensin II receptor blocker; MI, myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction.